FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 205	49
----------------------	----

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Chivukula Pad					2. Issuer Name and Ticker or Trading Symbol Arcturus Therapeutics Holdings Inc. [ ARCT]								(Che	eck all app Direc	,	ng Pers	on(s) to Is 10% Ov Other (s	vner	
(Last)	(Fi	rst) (N	∕liddle)												below	<i>ı</i> ) ``		below)	·
C/O ARCTURUS THERAPEUTICS HOLDINGS INC.					3. Date of Earliest Transaction (Month/Day/Year) 01/04/2022									Chief	Scientific	Offic	er & CO	0	
10628 SCIENCE CENTER DRIVE, SUITE 250					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)															,	filed by On	e Repoi	rting Perso	on
SAN DIEGO CA 92121														Form filed by More than One Reporting Person					
(City)	(St	ate) (2	Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Exec ay/Year) if an		Deemed ecution Date, ny onth/Day/Year)		3. 4. Securitie Disposed (5) 5)		es Acquired (A Of (D) (Instr. 3,		(A) or 3, 4 and	Benefic	ies cially Following	Form:	Direct Indirect tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) (D)	or l	Price	Transa	action(s) 3 and 4)			,iiisti. 4)
Common Stock 01/04/2					/2022				S <sup>(1)</sup>		8,100	D		\$40	594,448		]	D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, rity or Exercise (Month/Day/Year) if any		n Date,	4. Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		str.	B. Price of Derivative Decurity Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y O F D oi (i)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisa	able	Expiration Date	Title	Amo or Num of Shar	ber					

## **Explanation of Responses:**

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

/s/ Ilan Katz, attorney-in-fact 01/06/2022

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.